Phase II study evaluating oral vinorelbine as a single agent in patients with hormone receptor breast cancer with bone metastases previously treated by a hormone therapy
Phase II study evaluating oral vinorelbine as a single agent in patients with hormone receptor breast cancer with bone metastases previously treated by a hormone therapy
Phase II study evaluating oral vinorelbine as a single agent in patients with hormone receptor breast cancer with bone metastases previously treated by a hormone therapy
Statut
Status :
Terminé
Type d'étude
Phase II
Age Min.
18
Ans
Age Max.
85
Ans
Genre
Femme
Aire thérapeutique :
Oncologie
Maladie :
Cancer du sein
Traitement :
Vinorelbine (Navelbine® Oral)
Phase :
Phase II
Date de début de l'étude :
10 Avril 2010
End date :
17 Juin 2015
Identifiant de l'essai :
PM0259 CA 228 BO
Identifiant EudraCT/CTIS :
2009-014497-18
Envoyer par email